GLP-1 access in Connecticut: telehealth rules, licence lookups and Medicaid coverage

The card above is Connecticut's record from our state data file, and the sections below say what each line means and where it comes from. Rules on this page were checked on September 4, 2026; the linked sources are the authority if anything has moved since.

Who licenses prescribers in Connecticut

Physicians who treat patients located in Connecticut are licensed by the Connecticut Medical Examining Board (DPH eLicense). The board's lookup is at www.elicense.ct.gov/Lookup/LicenseLookup.aspx, which loaded when we checked on September 4, 2026. Nurse practitioners are licensed by the state nursing board and physician assistants by the medical board or their own board, depending on the state; the prescriber licence explainer walks through each search and what an active record does and does not tell you. Cross-check the name against the federal NPI Registry, which lists every US prescriber with credential and practice location.

The pharmacy that fills the prescription is licensed by the Connecticut Commission of Pharmacy. That includes pharmacies in other states that ship to a Connecticut address; they hold a non-resident licence from the same board. The Compounding Explained site covers what to search for once you are on the board site.

Telehealth prescribing in Connecticut

Connecticut allows a prescription for a non-controlled drug after a telehealth visit, with conditions. A Connecticut-licensed telehealth provider may treat and prescribe non-controlled drugs to a new patient without an in-person exam if using real-time two-way or store-and-forward technology, has the patient's medical history, meets the in-person standard of care (physical exam may be done via peripheral devices) and obtains consent; Schedule I-III drugs are barred except non-opioid Schedule II/III for psychiatric or substance use disorders. The text we read is Conn. Gen. Stat. § 19a-906(b)(1), (c), on September 4, 2026. For a prescriber licensed elsewhere, the same text describes an out-of-state route: § 19a-906(a)(12)(B): out-of-state mental/behavioral health providers could register with DPH, but only 'on or before June 30, 2025'; no general out-of-state physician registration seen Read the condition carefully before assuming a questionnaire-only program meets it.

Connecticut participates in the Interstate Medical Licensure Compact, the expedited licensing route for physicians who already hold a full licence in another member state. A compact licence is a full Connecticut licence and shows up on the board lookup like any other. Issuing letters of qualification and licences (Commission map dated March 15, 2026). None of this covers controlled substances, which add a federal layer; GLP-1s are not controlled. The cross-state telehealth explainer has the general pattern.

Medicaid and anti-obesity drugs in Connecticut

As of January 2026, Connecticut Medicaid fee-for-service did not cover GLP-1s prescribed for obesity (Wegovy, Zepbound, Saxenda for weight management). Source: KFF: Medicaid Coverage of and Spending on GLP-1s, Figure 1 state map (published January 16, 2026). KFF's map footnotes Connecticut as a state planning or considering coverage; check the current preferred drug list. Coverage of the same molecules for type 2 diabetes (Ozempic, Mounjaro) is a separate question and is usual. Federal law lets states exclude "agents used for weight loss" from Medicaid drug coverage (42 U.S.C. 1396r-8(d)(2)), which is why coverage varies state by state and can change with a budget. Managed-care plans in Connecticut may follow the state list or their own; the preferred drug list explainer shows where to look.

Compounded GLP-1s in Connecticut

We have not found a Connecticut-specific statute, rule or board notice on compounded GLP-1s that we could verify, so this page does not state one. The Connecticut Commission of Pharmacy is the regulator for a 503A pharmacy in the state and for non-resident pharmacies shipping into it; its newsletters and board minutes are where a state position would appear. The federal baseline applies everywhere: FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025, and after the enforcement-discretion periods it announced (503A pharmacies through February 18, 2025 for tirzepatide and April 22, 2025 for semaglutide) pharmacies may not compound what is essentially a copy of an approved product outside the narrow exceptions in federal law (FDA statement). On March 3, 2026 FDA sent warning letters to 30 telehealth companies over the marketing of compounded GLP-1s (FDA press release). Compounded semaglutide and tirzepatide are not FDA approved and are not interchangeable with Wegovy, Zepbound, Ozempic or Mounjaro.

Before you buy from a telehealth offer in Connecticut

1. Ask for the prescriber's full name and look it up on the Connecticut Medical Examining Board (DPH eLicense) lookup above. An active licence in Connecticut is the minimum, not an endorsement.
2. Ask which pharmacy will fill the prescription and check it on the Connecticut Commission of Pharmacy site, including a non-resident licence if the pharmacy is elsewhere.
3. If the product is compounded, expect it to be described as compounded and not FDA approved, and ask for the certificate of analysis. The Compounding Explained site has a vetting checklist; the FormBlends regulatory status page tracks the federal position.
4. Price the offer against brand self-pay programs and other compounded programs using the GLP-1 Pricing Index and the FormBlends cost report, and use the clinic fit quiz to decide which care model suits you. If you are new to tirzepatide, the FormBlends tirzepatide introduction covers the drug itself, and the FormBlends directory lists licensed providers and pharmacies.